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cense. httpAbstract Our previous published data detected higher expression of total and active mitogen activated
protein kinase (MAPK) in the epithelial vs. stromal cells of the endometrium. In the present work we
compared the expression of ERK1/2 MAPK and estrogen receptor a (ERa) in epithelial versus stromal
cells in benign human endometrial tissues. Laser capture microdissection was used to separate glandular
epithelium and stromal cells from six frozen, proliferative phase endometrial specimens.
Total and phosphorylated levels for ERK1/2 and ERa were measured by quantitation of signals from
Western blots using speciﬁc antibodies against the active and total forms of ERK1/2 and against ERa.
When the level of the proteins was quantitated and normalized to b actin from microdissected stroma
and epithelium, no signiﬁcant difference was detected in the levels of these proteins between the two
tissue compartments. There was a trend toward higher expression in the stroma vs. epithelium, respec-
tively (active ERK1/2 0.45 ± 0.17 vs. 0.2 ± 0.65; total ERK1/2 0.54 ± 0.35 vs. 0.28 ± 0.23; ERa
0.82 ± 0.28 vs. 0.54 ± 0.18; n= 6). These data demonstrate that there are comparable levels of
ERa (P= 0.41), total ERK1/2 (P= 0.18) and active ERK1/2 (P= 0.13) in the stroma and epithelium
of proliferative phase endometrium with a trend toward higher expression of these proteins in the stro-
mal compartment.
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There is growing interest in studying the distribution of mito-
gen activated protein kinase (MAPK) in different tissue com-
partments to identify a target tissue compartment that would
mediate the effects of novel signal transduction inhibitors that
target the MAP kinases. Interference with MAP kinase signal-
ing has the potential to beneﬁt therapies targeting the estrogen
receptor (ER) in the endometrium. The antiestrogen tamoxifen
blocks ER function, which is the basis for tamoxifen use in
breast cancer. However, tamoxifen exhibits estrogen-like
exhibits estrogen-like
ational Cancer Institute, Cairo University.
.001
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ated with abnormal endometrial proliferation that may pro-
gress to endometrial carcinoma. Experimental evidence has
shown that the extracellular signal-regulated kinase 1 and 2
(ERK1/2) [P44/42 MAP kinase] pathway cross-talks to ER
and promotes the estrogen-like action of tamoxifen most nota-
bly in estrogen dependent tumors [13,17]. This likely occurs
through phosphorylation of ER as well as reciprocal activation
of ERK1/2 by estrogens [21].
Interactions between stroma and epithelium play an impor-
tant role in the growth and differentiation of endometrium [4].
ER-dependent proliferation may be mediated by direct action
of estrogen on epithelial ER and/or an indirect effect through
the stromal ER. Animal models suggest that the stroma directs
the epithelial response to estrogen [6,5]. It was shown that
stromal ER directs the epithelium to respond to estrogen with
proliferation in neonatal mice [20]. In other studies where
separated endometrial epithelial and stromal cells were recom-
bined and grown in athymic mice, the ER positive stroma was
important as an interpreter of the estrogenic proliferation
signal to the glandular epithelium [15,27]. It is likely that estro-
gen regulates transcription in a gene speciﬁc manner through
ER present in both stroma and epithelium [16,22].
Bouchard et al. reported intense and frequent glandular
and stromal immunoreactivity of ER during the mid prolifer-
ative phase. During the mid and late secretory phase, ER
immunoreactivity almost disappeared from the glandular epi-
thelial cells [7]. Others found that the highest concentration
of ER was detected in both epithelial and stromal cells during
the late proliferative phase and decreased in the secretory
phase [2,18,19,23].
In our previous study [9] we found elevated active and total
ERK 1/2 in glandular epithelium in comparison to the stromal
cells in proliferative phase endometrium using immunohisto-
chemistry (IHC) in formalin-ﬁxed parafﬁn embedded sections
in three out of six cases used in the present study. Laser cap-
ture microdissection (LCM) offers a method to separate cell
types from heterogeneous tissues using standard microscopic
visualization for subsequent analysis. The selected cells are re-
moved by laser pulses and captured on a thermoplastic cap
where the captured cells can be visualized and display intact
architecture. Distinct tissue morphology must be maintained
by proper trimming and staining to accurately separate the
cells from frozen sections most notably because the sections
are relatively thick and no glass coverslip will be applied to
the sections [24]. Other methods used to separate tissues such
as enzymatic techniques employing 1% trypsin followed by
mechanical manipulations do not allow for completely accu-
rate separation of stroma and epithelium [4].
No studies have examined the quantitative expression of
ER or ERK1/2 kinase from glandular endometrial epithelium
and stroma cells separately excised by LCM. This approach
provides a mean to accurately quantitate and compare expres-
sion levels of these proteins among the tissue compartments.
Materials and methods
Six freshly frozen, human endometrial tissues that showed
higher expression of ERK 1/2 by Western blot in our previous
study [9] were obtained from the Cooperative Human Tissue
Network (CHTN, Columbus, OH). The histological type was
normal mid proliferative phase endometrium. The tissues wereimmediately snap frozen in liquid nitrogen after resection to
minimize protein degradation and dephosphorylation of the
kinases. Each endometrial tissue (0.2–1.5 g) was cut into four
pieces and one of them was embedded in M1 embedding ma-
trix for frozen sectioning. The tissue was placed in an empty
cryomold on dry ice, and M1 matrix was poured into the
cryomold. The blocks were kept at 80 C until sectioning.
Cyrosections were prepared (8 lm) (Leica CM 3050 S cryostate,
Meyer Instruments, Inc., Houston, TX) on Poly-L-lysine glass
slides, placed on dry ice and stored at 80 C until LCM. One
section was used at a time, ﬁxed with 70% ethanol at 4 C for
60 s, followed by deionized water for 30 s., staining with Nu-
clear Fast Red (NFR) containing protease inhibitor cocktail
(150 ll of Sigma protease inhibitor cocktail in 10 ml of stain) for
60 s, followed by 2 · 2 min dH2O. The slide was dehydrated
with successive washes of 70%, 95% and 100% ethanol for
30 s. each, xylene 2 · 5 min. and air dried for 15 min.
Laser capture microdissection
The slides were microdissected using an Arcturus PixCell II sys-
tem (PixCell 100;Arcturus,MountainView, CA) to separate the
endometrial glandular epithelium from the stromal tissue with
careful histological evaluation by the study pathologist
(MMD). For each case, 25,000–35,000 laser pulses were used
with the amplitude and pulse duration ﬁxed at 45 mW for
30 ms and the diameter of the laser beam adjusted to 7.5 lm.
The microdissected tissue was adhered to caps (CapSure LCM
Caps, Arcturus, Mountain View, CA). The caps were inverted
in matching microfuge tubes containing 50 ll of lysis buffer
[10 mM Tris pH 8, 0.4 M sodium chloride, 50 mM potassium
phosphate, 50 mM sodium ﬂuoride, 10 mM sodiummolybdate,
2 mMEDTA, 2 mMEGTA, 1 mM sodium vanadate, 0.1% tri-
ton-X 100, 10 mM b mercaptoethanol, 0.1% SDS, 0.5% IGE-
PAL CA-630, protease inhibitor cocktail (Sigma, St. Louis,
MO) and 0.1 mM phenylmethyl-sulfonyl ﬂuoride (PMSF)].
Proteins were extracted by brief vortexing of the tube and centri-
fugation at 20,000·g in a microfuge to clear the supernatant.
12.5 ll of 5· SDS puffer was added to the cleared supernatant
and the sample was stored at 20 C until use.
Western blot analysis
Polyclonal anti-rabbit antibodies against total and phosphory-
lated (active) kinases for human p42/44 MAP kinase (ERK1/
2), were purchased from Cell Signaling Technology, (Beverly,
MA, USA), monoclonal anti-mouse antibody to estrogen
receptor (NCL-ER-6F11) was purchased from Novo Castra,
(Newcastle, UK), and antibody to b actin was purchased from
Santa Cruz Biotechnology, (Santa Cruz, CA). Secondary anti-
bodies (biotinylated anti-rabbit, anti-mouse and anti-goat IgG
(H + L)), and horseradish peroxidase streptavidin were pur-
chased from Vector Laboratories, (Burlingame, CA). Equal
amounts of protein extraction were separated by electrophore-
sis on a 10% SDS–PAGE gel. The gel was transferred to a
nitrocellulose membrane, and blocked in 5% nonfat milk in
Tris-buffered saline/Tween 20 (TBST; 10 mM Tris, pH 8,
150 mM NaCl and 0.1% Tween-20) for 1 h at room temp., fol-
lowed by 3 · 5 min. washes with TBST. The membranes were
incubated with each primary antibody overnight in 5% dried
milk/TBST at 4 C at a 1:500 dilution for ERK 1/2 and a
1:40 dilution for the estrogen receptor antibody. Following
ERa and ERK1/2 MAP kinase expression 39primary antibody incubation, the membranes were washed
with TBST 3 · 5 min. and then incubated with secondary bio-
tinylated IgG (3 lg/ml) for 1 h at room temp. Following
3 · 5 min washes with TBST, the membranes were incubated
with horseradish peroxidase streptavidin (2 lg/ml) for 1 h at
room temp., and washed 3 · 5 min. with TBST. The signal
was developed with the addition of enhanced chemilumines-
cence (ECL) solution (1:1 mixture of solution A + B (A)
9.9 ml of 0.1 M Tris pH 8.5 + 100 ll luminol + 44 ll P-cou-
maric, (B) 10 ml of 0.1 M Tris pH 8.5 + 6 ll hydrogen perox-
ide). The membranes were exposed to Kodak Imager
instrument for signal quantitation as described below and also
exposed to a Kodak XOMAT ﬁlm for 15 min. Samples that
showed no Western blot signal were repeated two times to as-
sure there were no problems with the Western blot procedure.
To assess for protein degradation and to normalize protein
load among samples, the membranes were incubated with anti-
body against b actin after stripping the blots (see below).
Stripping of membranes
After performing Western blotting using antibodies to the
kinases and ER, the membranes were incubated in stripping
buffer (62.5 mM Tris–HCl (pH 6.8), 2% SDS and 100 mM
b-mercaptoethanol) for 30 min., at 55 C with rocking to remove
bound antibodies and prepare the membrane to be re-probed
with antibody against b-actin (2 lg/ml) as described above.
Quantitation of the ECL signal
The ECL signal was quantitated using a Kodak Digital Science
1D image analysis software station 440 system (Kodak Digital
Science, Rochester, NY) to compare the level of activated and
total kinases and ERa between glandular epithelium and stro-
ma cells for each protein separately among samples. The sig-
nals measured for these antibodies were divided by the value
for b-actin to normalize for protein load.
Statistical analysis
SPSS software for Windows (version 11.5.1) was used in ana-
lyzing the Western blot data. Values were reported as mean-
s ± SEM. The Mann–Whitney U test was used to analyze
the differences in the expression of total ERK1/2 and the inde-
pendent t-test was used to analyze the differences in the expres-
sion of active ERK1/2 and ERa between glandular epithelium
and stromal cells. P 6 0.05 was considered signiﬁcant.
Results
Our objective in the present study was to quantitatively com-
pare the expression of active and total ERK 1/2 MAP kinase
and ERa in laser captured microdissected benign proliferative
glandular epithelium versus stromal cells from freshly frozen
endometrial tissue samples after brief ﬁxation in 70% ethanol
and staining with NFR. All six cases studied were normal, mid
proliferative phase endometrium (Fig. 1A and B). The glands
were uniform, tubular, lined by one layer of columnar cells,
showing frequent normal mitoses and surrounded by dense cel-
lular stroma. The same ﬁelds are shown in Fig. 1C and D after
LCM of the glandular epithelium but with NFR stain.We observed that the tissue architecture was well preserved
and that tissues were easily removed by LCM. From six spec-
imens there was no signiﬁcant difference in the level of active
and total ERK1/2 and ERa between stroma and epithelium
(Fig. 2) when the absolute Western blot signal of these anti-
bodies was normalized to b actin [active ERK1/2
(0.45 ± 0.17 vs. 0.2 ± 0.65) total ERK1/2 (0.54 ± 0.35 vs.
0.28 ± 0.23) and ERa (0.82 ± 0.28 vs. 0.54 ± 0.18)] in stro-
mal versus glandular epithelial cells, P= 0.13, 0.18 and 0.41,
respectively. Similar results were found for active ERK1/2
when the signal was normalized to the total ERK1/2 signal
rather than b actin (data not shown). However, there was a
trend toward higher levels of these proteins expressed in stro-
ma vs. epithelium with the increased expression of active
ERK1/2 in the stroma approaching signiﬁcance (P= 0.13).
A larger sample size than the one used in this report may be
used in future studies to determine if actual differences exist.
Discussion
In the present work we measured both total and active levels for
ERK1/2 MAPK and ERa in glandular epithelium versus stro-
mal cells from six freshly frozen, mid proliferative phase human
endometrial tissue specimens that showed the highest expression
of ERK1/2 in our previous study bymeans ofWestern blot after
tissue homogenization and total protein extraction.
In our previous IHC results, where three out of the six cases
used in the present study were stained with the same antibodies
for active and total ERK 1/2, we found an elevated active and
total ERK 1/2 in the glandular epithelium compared to mild
expression in the stromal compartment [9]. The ERa immu-
no-staining also appeared to be more intense in the epithelial
compartment compared to the stromal compartment in the
same cases studied (data not shown) giving the impression that
the glandular epithelial expression of ERK 1/2 and ERa is
higher than that in the stroma.
LCM offers an advantage over standard IHC by providing
precise quantitative measurement of the expression of proteins
in speciﬁc tissue sub-compartments with normalization to stan-
dard proteins [10,24]. In contrast to what we and others have
found using IHC for ERa [2,9,18,19,23] we detected no signiﬁ-
cant difference in the expression of total ERK1/2, active
ERK1/2 and ERa between stroma and epithelium, with a trend
toward higher expression of these proteins in the stroma.
Although the absolute quantitated values were higher in the
glandular epithelium compared to the stroma, when normalized
to b actin the differences were not signiﬁcant. The relative
expression of these proteins as assessed by IHCmay be mislead-
ing since normalization to b actin is not performed during IHC.
Our work of quantitative measurement of stromal and epi-
thelial ER using LCM conﬁrms the signiﬁcant stromal ERa
expression when compared to the epithelium and supports a
role for the stromal ERa. Yamashita and co-workers used
IHC in neonatal CD-1 mouse uterus and found that the epithe-
lial cells of the endometrium expressed ER but at low levels
compared to the stroma [27,26]. Garcia et al. reported that
ERa is expressed in both human endometrial glandular epithe-
lium as well as stroma cells [14]. Cooke et al. reported that epi-
thelial ERa is not necessary for estrogen induced epithelial
proliferation and that the stromal component has the most
important tissue compartment for proliferation [8]. Multiple
reports suggest that the stromal ER is important for the
Figure 1 Representative cases of mid proliferative phase endometrial tissue sections used for laser capture microdissection. (A and B)
Formalin ﬁxed parafﬁn embedded sections stained with H&E showing uniform tubular glands lined by one layer of columnar cells
surrounded by cellular stroma. (C and D) The same cases but cryo-sectioned and stained with NFR after a brief 70% alcohol ﬁxation and
subjected to LCM to separate the glandular epithelial cells from the stromal cells. Note the empty ﬁelds after extraction of the glands.
Original magniﬁcations are (·200).
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Figure 2 Expression of ERK1/2 kinase and ERa in microdissected endometrial stromal and glandular epithelium. Normal proliferative
human endometria (n= 6) were subjected to laser capture microdissection to separately excise stroma and glandular epithelium. The
micro-dissected cells were lysed in lysis buffer and the cleared extract was electrophoresed on SDSPAGE gels prior to Western blotting
with antibodies against total and phosphorylated forms of ERK1/2 kinase, ERa and antibody to b actin. Western blot signals were
digitally quantitated using Kodak Image Station. Quantitated signals are plotted in (A–C). Representative Western blots are shown in (D)
(42 and 44 kDa and 66 kDa for ERK1/2 and ERa, respectively). Values shown are ±standard error of the mean.
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[2,4,5,8,12].
Estrogen is a well-known proliferative stimulus for glandular
epithelial cells in the endometrium under normal and patholog-
ical conditions. Estrogen action is mediated by ERa and ERb
[11,25]. After binding to estrogen or selective estrogen receptor
modulators (SERMs) such as tamoxifen, ERa is targeted to the
nucleus where it regulates transcription of estrogen responsive
genes [1,28]. As stated above, the ER and ERK1/2 signaling
pathways crosstalk to one another, hence it is important to
understand the relative expression levels of both proteins within
the same tissue compartments. To the best of our knowledge, no
study has attempted to quantitatively compare the expression of
ER and ERK1/2 in well-separated different uterine compart-
ments such as glandular epithelium versus stroma despite the
intimate interaction between theERandMAPKpathways. This
study has performed a quantitative comparison of the expres-
sion of these proteins between endometrial stroma and epithe-
lium and found that ER, total and active ERK1/2 kinase
levels are comparable in benign, proliferative phase endometrial
stroma and epithelium. Future studies may further compare
expression of kinases and assess the signiﬁcance of the stromal
and epithelial kinase activity during the menstrual cycle and in
benign and malignant endometrium with regard to tumor
growth and ER action.
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